HLA and risk of diffuse large B-cell lymphoma after solid organ transplantation

Hussain, Shehnaz K.; Makgoeng, Solomon B.; Everly, Matthew J.; Goodman, Marc T.; Martínez-Maza, Otoniel; Morton, Lindsay M.; Clarke, Christina A.; Lynch, Charles F.; Snyder, Jon; Israni, Ajay; Kasiske, Bertram L.; Engels, Eric A.

doi:10.1097/TP.0000000000001025

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

HLA and risk of diffuse large B-cell lymphoma after solid organ transplantation

Published Date:

Nov 2016

Publisher's site:

http://dx.doi.org/10.1097/TP.0000000000001025 New Site Icon

Source:

Transplantation. 100(11):2453-2460.

[PDF-116.45 KB]

Details:

Personal Authors:

Hussain, Shehnaz K. ; Makgoeng, Solomon B. ; Everly, Matthew J. ; Goodman, Marc T. ; Martínez-Maza, Otoniel ; ... More ▼

Keywords:

[+]

Pubmed ID:

26636741

Pubmed Central ID:

PMC4893345

Description:

Background

Solid organ transplant recipients have heightened risk for diffuse large B-cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established.

Methods

We examined 172,231 U.S. kidney, heart, pancreas, and lung recipients transplanted between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number.

Results

Compared to recipients who had two HLA-DR mismatches, those with zero or one mismatches had reduced DLBCL risk, (zero: IRR=0.76, 95%CI=0.61–0.95; one: IRR=0.83, 95%CI=0.69–1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset, DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all three loci (P=0.0003). Several individual recipient HLA-A, -B, -C, -DR, and –DQ antigens were also associated with DLBCL risk, including DR13 (IRR=0.74, 95%CI=0.57–0.93) and B38 (IRR=1.48, 95%CI=1.10–1.93), confirming prior findings that these two antigens are associated with risk of infection-associated cancers.

Conclusions

In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients, or chronic immune stimulation.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

Main Document Checksum:

[+]

Supporting Files:

	NIHMS731911-supplement-Supplemental_Digital_Content_to_Be_Published_1.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	NIHMS731911-supplement-Supplemental_Digital_Content_to_Be_Published_2.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	nihms731911.nxml	text/xml

No Related Documents.

You May Also Like:

Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients

Personal Author:

Mahale, Parag; Shiels, Meredith S.; Lynch, Charles F.; Engels, Eric A.;

Published:

Sep 02 2017

Source:

Am J Transplant. 18(2):453-461

Description:

Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus-infected people. Using data from the US transplant registry linked with 17 cancer registries (1987-2014), we studied PCNSL and ...

File Type:

[PDF - 464.57 KB]
Cancer Risk Following ABO Incompatible Living Donor Kidney Transplantation (1)

Personal Author:

Hall, Erin C.; Engels, Eric A.; Montgomery, Robert A.; Segev, Dorry L;

Published:

Sep 15 2013

Source:

Transplantation. 96(5):476-479.

Description:

Background : Recipients of ABO incompatible (ABOi) living donor kidney transplants often undergo more intense immunosuppression than their ABO compatible (ABOc) counterparts. It is unknown if this difference leads to higher cancer risk after transpla...

File Type:

[PDF - 40.21 KB]
Contribution of solid organ transplant recipients to the pediatric non-Hodgkin lymphoma burden in the United States

Personal Author:

Yanik, Elizabeth L.; Shiels, Meredith S.; Smith, Jodi M.; Clarke, Christina A.; Lynch, Charles F.; Kahn, Amy R.; Koch, Lori; Pawlish, Karen S.; Engels, Eric A.;

Published:

Jul 31 2017

Source:

Cancer. 123(23):4663-4671

Description:

Background : Pediatric solid organ transplant recipients have 100–200 times higher risk of non-Hodgkin lymphoma (NHL) than the general pediatric population. Consequently, transplant-related NHLs may contribute considerably to the pediatric NHL burd...

File Type:

[PDF - 155.43 KB]
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States

Personal Author:

Gibson, Todd M.; Engels, Eric A.; Clarke, Christina A.; Lynch, Charles F.; Weisenburger, Dennis D.; Morton, Lindsay M.;

Published:

Apr 18 2014

Source:

Am J Hematol. 89(7):714-720.

Description:

Non-Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post-transplantation non-Hodgkin lymph...

File Type:

[PDF - 331.46 KB]
Risk of lymphoma subtypes after solid organ transplantation in the United States

Personal Author:

Clarke, C A; Morton, L M; Lynch, C; Pfeiffer, R M; Hall, E C; Gibson, T M; Weisenburger, D D; Martínez-Maza, O; Hussain, S K; Yang, J; Chang, E T; Engels, E A;

Published:

Jun 11 2013

Source:

Br J Cancer. 2013; 109(1):280-288.

Description:

Background: : Solid organ transplant recipients have high risk of lymphomas, including non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). A gap in our understanding of post-transplant lymphomas involves the spectrum and associated risks of their m...

File Type:

[PDF - 182.41 KB]